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Abstract
Background: FDG PET-CT is generally not suitable for diagnosing prostate cancer because of low
glycolysis of the tumor cells. Neuroendocrine differentiation of the prostate cancer is often
associated with early visceral metastasis and dismal prognosis, which is resulted from changed
metabolic and regulatory pathways.
Case presentation: A case is reported in this paper that FDG PET-CT demonstrates intense
uptake of neuroendocrine tumor of the prostate and multiple metastases.
Conclusion: There is high glycolysis and strong FDG-avidity of neuroendocrine tumor of the
prostate, which is similar to that of high grade of neuroendocrine tumor in other tissue and organs.
In some selected cases of prostate neuroendocrine cancer, whole body FDG PET-CT may be
helpful for detection of metastatic disease.
Background
Positron emission tomography (PET) is a new imaging
modality which has been widely used for detection of
metastasis in various malignancies. The most used radi-
otracer, F18-fluorodeoxyglucose (FDG) is for evaluation
of glycolysis and glucose transporter expression. It is well
known that most of malignant tumors display increased
glucose metabolism. Unfortunately FDG-PET has not
been very helpful in prostate cancer because of low glyco-
lysis of the tumor cells. In addition, physiologic urinary
excretion of FDG can interfere with imaging of the pelvis
[1-3].
Neuroendocrine differentiation of the prostate cancer
contributes to the progression of the disease and often
associated with visceral metastases and dismal prognosis
[4,5]. We herein describe the case of a prostate cancer that
had neuroendocrine differentiation and multiple meta-
static lesions detected by FDG PET-CT.
Case presentation
A 79 year old male with a history of prostate cancer was
treated with external radiation and hormone a few years
ago. He recently developed gross hematuria and renal fail-
ure. CT scan showed bladder mass, hydronephrosis and
small lung nodules, but no liver lesion or retroperitoneal
lymphadenopathy was noted. The patient underwent
nephrostomies and prostate biopsy.
Immunohistochemical studies of the prostate tissue
revealed positive staining of the tumor cells for chrom-
ogranin, synaptophysin and neuro-specific enolase. The
samples were negative for cytokeratin and PSA. In view of
the patient's history of prostate adenocarcinoma, the find-
ings were consistent with a high grade of neuroendocrine
differentiation.
The patient's whole body bone scintigraphy was negative.
The medical oncologist recommended, the patient was
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also strongly interested in cystoprostatectomy with ileal
conduit followed by chemotherapy. As a final pre-surgical
work-up, the patient had FDG PET/CT, which demon-
strated tumor invasion and infiltration to the bladder as
well as multiple metastastic lesions in the liver, lungs and
lymph nodes (Figure 1, 2, 3, 4). Compared to a CT less
than two months earlier, PET-CT findings suggested
marked progression of prostate tumor and multiple new
metastases. Therefore, scheduled surgery was cancelled
and the patient was treated with chemotherapy (Topote-
can) in a hospice facility.
Discussion
Neuroendocrine tumor of the prostate is featured by early
visceral rather than bone metastases [6]. In this case, a CT
scan two months earlier was negative in the liver and for
lymphadenopathy, but FDG PET-CT demonstrated exten-
sive hepatic lesions as well as nodal and lung metastases
while bone scan was still negative.
FDG-PET scan has its advantages of metabolic and molec-
ular imaging, therefore early detection of malignant dis-
ease. In addition, routine whole body imaging make it
best imaging modality for staging and restaging of most of
the malignant diseases. In prostate adenocarcinoma,
FDG-PET often does not display increased uptake. Liu et
al found only 4% sensitivity for detecting primary prostate
cancer with FDG-PET [7]. But using continuous bladder
irrigation, Oyama et al found an increased sensitivity for
detecting the prostate tumor [8]. Patients showing
increasing prostate specific antigen (PSA) after definite
local therapy for prostate cancer represent a diagnostic
dilemma. FDG-PET may identify local recurrence and dis-
tant metastases with increasing PSA [9]. In addition, Mor-
ris et al reported that using PSA levels, bone scintigraphy
and soft tissue imaging as references, FDG-PET might be a
promising outcome measure after chemotherapy in pros-
tate cancer [10].
With neuroendocrine differentiation, the tumor has dif-
ferent biological behavior [4]. The cells involved in this
process secrete a variety of factors that can influence
growth patterns and metabolic pathways [11]. This case
suggests very high glycolysis and strong FDG-avidity of
neuroendocrine tumor of the prostate, which is similar to
that of high grade of neuroendocrine tumor in other tis-
sue and organs [12].
To our knowledge, this is the first report of FDG-PET
application in neuroendocrine tumor of the prostate and
metastatic disease. In some selected cases of neuroendo-
crine tumor of the prostate, whole body FDG-PET may be
helpful for detection of metastasis and therefore change
patient's management.
Conclusion
Neuroendocrine tumor of the prostate demonstrates dif-
ferent metabolic characteristics from adenocarcinoma. It
has high FDG avidity and often demonstrates early vis-
ceral metastases. In some selected cases, FDG-PET may be
Maximum intensity projection (MIP) of the whole body FDG  PET-CT imaging Figure 1
Maximum intensity projection (MIP) of the whole body FDG 
PET-CT imaging. There is intense uptake in the prostate 
tumor with invasion and infiltration to the bladder wall. Mul-
tiple FDG-avid metastatic lesions are noted in the liver, Lungs 
and lymph nodes of the mediastinum and retroperitoneum.World Journal of Surgical Oncology 2008, 6:64 http://www.wjso.com/content/6/1/64
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Neuroendocrine differentiation of the prostate cancer displays high grade of FDG uptake on transaxial PET-CT images, which  is different from that noted in most of adenocarcinoma of the prostate Figure 2
Neuroendocrine differentiation of the prostate cancer displays high grade of FDG uptake on transaxial PET-CT images, which 
is different from that noted in most of adenocarcinoma of the prostate.
FDG PET-CT images demonstrate multiple necrotic hepatic metastases while bone scan and CT two months earlier were neg- ative Figure 3
FDG PET-CT images demonstrate multiple necrotic hepatic metastases while bone scan and CT two months earlier were neg-
ative.
FDG PET-CT images demonstrate a 1.3 cm aortocaval lymph node with intense uptake consistent with metastatic disease Figure 4
FDG PET-CT images demonstrate a 1.3 cm aortocaval lymph node with intense uptake consistent with metastatic disease.Publish with BioMed Central    and   every 
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an ideal imaging modality and helpful for identifying
metastatic disease.
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